Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Featherstone, Robert E ^a   Phillips, Jennifer M ^b   Thieu, Tony ^a   Ehrlichman, Richard S ^a   Halene, Tobias B ^a   Leiser, Steven C ^c   Christian, Edward ^c   Johnson, Edwin ^c   Lerman, Caryn ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT ST MARY S UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; DIHYDRO BETA ERYTHROIDINE; ISPRONICLINE; METHYLLYCACONITINE; NICOTINE TARTRATE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; EVOKED AUDITORY RESPONSE; GAMMA RHYTHM; HIPPOCAMPAL CA3 REGION; LATENT PERIOD; MALE; MOLECULAR DYNAMICS; MOUSE; NEUROFEEDBACK; NEUROMODULATION; NONHUMAN; OSCILLATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR SENSITIVITY; SPIKE WAVE;

ACONITINE; ANIMALS; CALCIUM SIGNALING; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; HUMANS; MALE; MICE; NICOTINE; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC;

MUS;

EID: 84864089032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039775     Document Type: Article

References (52)

1. Boutros NN, Zouridakis G, Overall J, (1991) Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22: 40-45.
2. Boutros N, Zouridakis G, Rustin T, Peabody C, Warner D, (1993) The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res 47: 243-254.
3. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD, (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 18: 537-551.
4. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, et al. (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17: 639-654.
5. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, et al. (1998) Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44: 98-106.
6. Adler LE, Hoffer LD, Wiser A, Freedman R, (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861.
7. Maxwell CR, Kanes SJ, Abel T, Siegel SJ, (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129: 101-107.
8. Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, et al. (2003) Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res 992: 85-95.
9. Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, et al. (2004) The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res 29: 1179-1188.
10. Metzger KL, Maxwell CR, Liang Y, Siegel SJ, (2007) Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry 61: 23-30.
11. Siegel SJ, Maxwell CR, Majumdar S, Trief DF, Lerman C, et al. (2005) Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience 133: 729-738.
12. Umbricht D, Vyssotky D, Latanov A, Nitsch R, Brambilla R, et al. (2004) Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res 1019: 189-200.
13. Siegel SJ, Connolly P, Liang Y, Lenox RH, Gur RE, et al. (2003) Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28: 675-682.
14. Ehrlichman RS, Maxwell CR, Majumdar S, Siegel SJ, (2008) Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J Cogn Neurosci 20: 1403-1414.
15. Phillips JM, Ehrlichman RS, Siegel SJ, (2007) Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma. Neuroscience 144: 1314-1323.
16. Crawford HJ, McClain-Furmanski D, Castagnoli N Jr, Castagnoli K, (2002) Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers. Neurosci Lett 317: 151-155.
17. Lewis DA, Hashimoto T, Volk DW, (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
18. Gandal MJ, Edgar JC, Klook K, Siegel SJ, (2011) Gamma synchrony: Towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology.
19. Uhlhaas PJ, Singer W, (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11: 100-113.
20. Benchenane K, Tiesinga PH, Battaglia FP, (2011) Oscillations in the prefrontal cortex: a gateway to memory and attention. Curr Opin Neurobiol 21: 475-485.
21. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
22. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, et al. (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24: 189-202.
23. Hashimoto K, Iyo M, Freedman R, Stevens KE, (2005) Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors. Psychopharmacology (Berl) 183: 13-19.
24. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, et al. (2009) Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65: 144-149.
25. Rudnick ND, Koehler C, Picciotto MR, Siegel SJ, (2009) Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology (Berl) 202: 745-751.
26. Wildeboer KM, Stevens KE, (2008) Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 1224: 29-36.
27. Stevens KE, Kem WR, Mahnir VM, Freedman R, (1998) Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 136: 320-327.
28. Damaj MI, Glassco W, Dukat M, Martin BR, (1999) Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291: 1284-1291.
29. Davis JA, Gould TJ, (2006) The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) 184: 345-352.
30. Gommans J, Stolerman IP, Shoaib M, (2000) Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39: 2840-2847.
31. Walters CL, Brown S, Changeux JP, Martin B, Damaj MI, (2006) The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology (Berl) 184: 339-344.
32. Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M, (2006) Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci 30: 19-20.
33. Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, et al. (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191: 919-929.
34. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, et al. (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10: 147-166.
35. Maxwell CR, Ehrlichman RS, Liang Y, Trief D, Kanes SJ, et al. (2006) Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 316: 315-324.
36. Maxwell CR, Liang Y, Weightman BD, Kanes SJ, Abel T, et al. (2004) Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29: 739-746.
37. Rudnick ND, Strasser AA, Phillips JM, Jepson C, Patterson F, et al. (2010) Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 12: 589-597.
38. Maxwell CR, Ehrlichman RS, Liang Y, Gettes DR, Evans DL, et al. (2006) Corticosterone modulates auditory gating in mouse. Neuropsychopharmacology 31: 897-903.
39. Delorme A, Makeig S, (2004) EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 134: 9-21.
40. Amann LC, Phillips JM, Halene TB, Siegel SJ, (2008) Male and female mice differ for baseline and nicotine-induced event related potentials. Behav Neurosci 122: 982-990.
41. Turek JW, Kang CH, Campbell JE, Arneric SP, Sullivan JP, (1995) A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. J Neurosci Methods 61: 113-118.
42. Stegelmeier BL, Hall JO, Gardner DR, Panter KE, (2003) The toxicity and kinetics of larkspur alkaloid, methyllycaconitine, in mice. J Anim Sci 81: 1237-1241.
43. Petersen DR, Norris KJ, Thompson JA, (1984) A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos 12: 725-731.
44. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, et al. (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280: 346-356.
45. De Biasi M, Dani JA, (2011) Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34: 105-130.
46. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, et al. (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312: 1213-1222.
47. Herrmann CS, Demiralp T, (2005) Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol 116: 2719-2733.
48. Basar E, Basar-Eroglu C, Karakas S, Schurmann M, (2001) Gamma, alpha, delta, and theta oscillations govern cognitive processes. Int J Psychophysiol 39: 241-248.
49. Basar-Eroglu C, Struber D, Schurmann M, Stadler M, Basar E, (1996) Gamma-band responses in the brain: a short review of psychophysiological correlates and functional significance. Int J Psychophysiol 24: 101-112.
50. Demiralp T, Basar-Eroglu C, Basar E, (1996) Distributed gamma band responses in the brain studied in cortex, reticular formation, hippocampus and cerebellum. Int J Neurosci 84: 1-13.
51. Demiralp T, Bayraktaroglu Z, Lenz D, Junge S, Busch NA, et al. (2007) Gamma amplitudes are coupled to theta phase in human EEG during visual perception. Int J Psychophysiol 64: 24-30.
52. Pantev C, Hoke M, Lutkenhoner B, Lehnertz K, (1991) Neuromagnetic evidence of functional organization of the auditory cortex in humans. Acta Otolaryngol Suppl 491: 106-114; discussion 115.